APA (7th ed.) Citation

Moreno-montañés, J., Sádaba, B., Ruz, V., Gómez-guiu, A., Zarranz, J., González, M. V., . . . Jimenez, A. I. (2014). Phase I Clinical Trial of SYL040012, a Small Interfering RNA Targeting [beta]-Adrenergic Receptor 2, for Lowering Intraocular Pressure. Molecular therapy, 22(1), 226. https://doi.org/10.1038/mt.2013.217

Chicago Style (17th ed.) Citation

Moreno-montañés, Javier, Belén Sádaba, Verónica Ruz, Almudena Gómez-guiu, Javier Zarranz, María Victoria González, Covadonga Pañeda, and Ana Isabel Jimenez. "Phase I Clinical Trial of SYL040012, a Small Interfering RNA Targeting [beta]-Adrenergic Receptor 2, for Lowering Intraocular Pressure." Molecular Therapy 22, no. 1 (2014): 226. https://doi.org/10.1038/mt.2013.217.

MLA (9th ed.) Citation

Moreno-montañés, Javier, et al. "Phase I Clinical Trial of SYL040012, a Small Interfering RNA Targeting [beta]-Adrenergic Receptor 2, for Lowering Intraocular Pressure." Molecular Therapy, vol. 22, no. 1, 2014, p. 226, https://doi.org/10.1038/mt.2013.217.